Sunesis Pharmaceuticals, Inc. Sunesis Pharmaceuticals, Inc. today announced that it has sold to SARcode its intellectual property and other assets in its LFA-1 inhibitor program previously licensed to SARcode for a total cash consideration of $2 million. As a ...
This letter proposes a new H-α-ρ method (H is the entropy, α is the average scattering mechanism, and ρ is the circular polarization correlation coefficient) for extracting the spatial distribution of collapsed buildings using RADARSAT-2 fine-mode polarimetric synthetic aperture radar (SAR) ...
“The completion of the Phase 1 study represents the first-in-man experience for SAR 1118 and an important step toward the development of a novel therapy for ocular inflammation,” said Tom Gadek, Ph.D., Chief Executive Officer of SARcode Corporation. “Based upon...
SAR 1118 demonstrated dose-dependent significant improvements (p<0.05) in inferior corneal staining over 12 weeks. As early as two weeks, a statistically significant(p<0.05) increase in tear production and improvement in visual-related functions (ability to read, drive at night...